// App-Quantinova.ai

: Sustained Long-Term Dupilumab Efficacy in Adult Patients With Moderate-to-Severe Atopic Dermatitis Transitioning From Weekly Dosing to Every Other Week: Results From an Open-Label Extension Trial

Researchers

Presenter

  • Lisa A. Beck

Principal Investigators

  • Mette Deleuran

  • H. Chih-ho Hong

  • David N. Adam

  • Iftikhar Hussain

  • Haixin Zhang

  • Arsalan Shabbir

  • Ainara Rodríguez Marco

  • Noah A. Levit

Medical Centers

  • University of Rochester Medcal Center, Rochester, NY

  • Aarhus University Hospital, Aarhus, Denmark

  • The University of British Columbia, Vancouver, BC, Canada

  • Probity Clinical Research, Waterloo, ON, Canada

  • University of Toronto, Toronto, ON, Canada

  • CCA Medical Research, Ajax, ON, Canada

  • Vital Prospects Clinical Research Institute, PC, Tulsa, OK, USA

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY

  • Sanofi Genzyme, Madrid, Spain

Locations

  • United States

  • United Kingdom

  • Canada

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

Disease

  • Atopic Dermatitis

Biomarkers

  • N/A

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • N/A

Study Id's

  • NCT01949311

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved